Warning Letter Record: Online Generic Medicine/www.onlinegenericmedicine.com (2026-09-23) — Unapproved New Drug/Misbranded (Internet Pharmacy)
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drug/Misbranded (Internet Pharmacy)
TL;DR
Key takeaway: The FDA Center for Drug Evaluation and Research (CDER) issued a warning letter to Online Generic Medicine/www.onlinegenericmedicine.com on September 23, 2026 (Reference: MARCS-CMS 737806), citing violations of the Federal Food, Drug, and Cosmetic Act for introducing unapproved and misbranded injectable semaglutide products into interstate commerce, including a product marketed as "Semanat Injection (Semaglutide)." The agency documented these violations during website reviews on August 26 and September 2, 2026, and stated that unapproved injectable drugs pose risks including contamination, counterfeits, inconsistent active ingredient amounts, and serious infections such as septicemia or sepsis. The FDA requested cessation of all unapproved and misbranded drug sales to U.S. consumers and warned that failure to address violations may result in seizure and injunction without further notice.
Argus analysis
# FDA Warning Letter Analysis: Online Generic Medicine
**Company and Violations**
Online Generic Medicine (www.onlinegenericmedicine.com) received a warning letter dated September 23, 2026, from the FDA's Center for Drug Evaluation and Research (CDER) for distributing unapproved and misbranded injectable semaglutide products to U.S. consumers. The FDA conducted website reviews on August 26 and September 2, 2026, identifying the company's sale of "Semanat Injection (Semaglutide)," which lacks FDA approval despite approved semaglutide versions existing on the U.S. market under brand names OZEMPIC and WEGOVY. The agency emphasized that unapproved injectable drugs pose heightened risks, including potential contamination, counterfeit ingredients, variable active ingredient concentrations, and serious infections such as sepsis.
**Regulatory Citations**
The violations cited sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C.). These citations address introducing unapproved new drugs into interstate commerce without section 505 applications, failing to include adequate directions for use on labeling, and dispensing prescription drugs without requiring valid prescriptions. Prescription drugs like semaglutide require healthcare practitioner supervision due to safety risks and are not amenable to self-diagnosis. The violation of section 503(b)(1) specifically indicates the company distributed controlled-access medications without pharmaceutical oversight.
**Response Timeline and Monitoring**
Online Generic Medicine has 15 business days from letter receipt to submit a written response to FDAInternetPharmacyTaskForce-CDER@fda.hhs.gov, detailing corrective actions and preventative measures. Compliance officers in the pharmaceutical distribution sector should monitor for potential seizure actions, injunctions, or international regulatory notifications if the company fails to cease operations. The FDA may coordinate with foreign regulatory agencies regarding product admissibility, indicating international enforcement may follow.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Online Generic Medicine/www.onlinegenericmedicine.com MARCS-CMS 737806 — September 23, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Recipient: Online Generic Medicine/www.onlinegenericmedicine.com United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States September 23, 2026 info@onlinegenericmedicine.com WARNING LETTER Reference Number: MARCS-CMS 737806 To Online Generic Medicine: This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website www.onlinegenericmedicine.com. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that you comply with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, FDA has observed that www.onlinegenericmedicine.com introduces into interstate commerce unapproved and misbranded injectable semaglutide drug products. There are inherent risks to consumers who purchase unapproved and misbranded drug products. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Furthermore, injectable drug products can pose a serious risk of harm to users because they bypass many of the body's natural defenses against toxic ingredients, toxins, or dangerous organisms that can lead to serious and life-threatening conditions such as septicemia or sepsis. Accordingly, FDA requests that www.onlinegenericmedicine.com cease offering any unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from harm. FDA Review Violations were identified and documented during a review of your website www.onlinegenericmedicine.com, FDA Establishment Identifier (FEI) 3048678145, on August 26, 2026, and September 2, 2026. Violations of the Federal Food, Drug, and Cosmetic Act On your website at internet address www.onlinegenericmedicine.com, you introduce into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), 301(d), 301(k), 502(f)(1), 503(b)(1), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 331(a), 331(d), 331(k), 352(f)(1), 353(b)(1), and 355(a)). The following are violations ide…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Is the FDA warning letter to Online Generic Medicine/www.onlinegenericmedicine.com publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/online-generic-medicinewwwonlinegenericmedicinecom-737806-09232026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Online Generic Medicine/www.onlinegenericmedicine.com (2026-09-23) — Unapproved New Drug/Misbranded (Internet Pharmacy). Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-online-generic-medicine-www-onlinegenericmedicine-com-2026-09-23-unapproved-drug
"Warning Letter Record: Online Generic Medicine/www.onlinegenericmedicine.com (2026-09-23) — Unapproved New Drug/Misbranded (Internet Pharmacy)." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-online-generic-medicine-www-onlinegenericmedicine-com-2026-09-23-unapproved-drug.
Argus HQ Research. "Warning Letter Record: Online Generic Medicine/www.onlinegenericmedicine.com (2026-09-23) — Unapproved New Drug/Misbranded (Internet Pharmacy)." Digital Empire Holdings LLC. Accessed October 9, 2026. https://argushq.ai/fda/warning-letter/fda-wl-online-generic-medicine-www-onlinegenericmedicine-com-2026-09-23-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_online_generic_medicine_www_onlinegenericmedicine_com_2026_09_23_unapproved_drug_2026,
title = {Warning Letter Record: Online Generic Medicine/www.onlinegenericmedicine.com (2026-09-23) — Unapproved New Drug/Misbranded (Internet Pharmacy)},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-online-generic-medicine-www-onlinegenericmedicine-com-2026-09-23-unapproved-drug},
note = {Accessed: October 9, 2026}
}